Developer docs
API playgroundTry for free, no card

Search company profiles

Brain+

Full company profile

uuid0000uuc

Namestring
Brain+
Legal namestring
Brain+ A/S
Websiteurl
brain-plus.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Brain+ A/S is a Danish digital therapeutics company founded in 2012 and headquartered in Copenhagen, operating with a headcount of 11–50 employees. The company develops mobile and web applications that deliver evidence-based Cognitive Stimulation Therapy (CST) for people with dementia, positioned as the only non-drug dementia therapy recommended by NICE and endorsed by Cochrane Reviews and SCIE. Its product portfolio centers on three offerings: Ayla, a UK-focused digital CST delivery platform for care homes and NHS memory clinics; CST-Therapist Companion, a Danish municipal channel product being scaled through a seven-municipality consortium with the Danish Alzheimer's Association and DanAge; and CST-Home Care, a product in development to extend therapy into patients' homes with family caregiver support.

The underlying platform combines a structured 14-session CST programme aligned to the official CST Manual, a library of over 180–200 clinically validated activities tagged by cognitive, physical, and emotional requirements, on-screen facilitator guidance that eliminates session preparation, and an outcomes-tracking framework that produces evidence aligned to the UK Single Assessment Framework and CQC reporting requirements. Brain+ monetizes Ayla via an annual SaaS subscription priced at £2,500 per care home per year, with no per-user fees and unlimited onboarding, training, and reporting included. Distribution is direct via the company website with a sales-led motion combining demo booking and quote-request CTAs, targeting care home CEOs, owners, managers, and activity coordinators, alongside NHS memory clinics and primary care providers.

The company's commercial strategy relies heavily on non-dilutive public funding: it secured three Danish public grants in 2023 totaling approximately DKK 7 million (including a DKK 3.5M Danish Business Authority grant for CST-Therapist Companion commercialization and an EUopSTART grant from the Danish Innovation Fund supporting an EIC Accelerator application for CST-Home Care). Geographic footprint is limited to the United Kingdom and Denmark, with no disclosed presence in other markets. The company is privately held and appears to be in an early commercial stage, using public grants in lieu of equity dilution to fund product and geographic expansion.

Short descriptiontext

Brain+ A/S is a Danish digital therapeutics company developing mobile and web applications that deliver evidence-based Cognitive Stimulation Therapy for dementia patients. It serves UK care homes, NHS memory clinics, Danish municipalities, and home-based dementia care through its Ayla, CST-Therapist Companion, and CST-Home Care products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
digital dementia therapy, cognitive stimulation therapy, dementia care software, digital therapeutics platform, care home technology
Industry3 codes
PRIMARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
SECONDARYHSABAEAJ
Dementia Care Coordination & Care Planning
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)
NAICS code2 codes
  • Services for the Elderly and Persons with Disabilities62412
  • Home Health Care Services6216
SIC code3 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Home Health Care Services8082
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Digital Therapeutics / Dementia Care Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Annual Care Home Subscription
TypeSubscription Recurring
Description

SaaS subscription model charging a flat annual fee per care home. Includes unlimited platform access, full onboarding and live support, outcomes reporting, and unlimited staff training per site. No per-user fees or hidden charges. Single pricing tier at £2,500/year per care home.

ayla-care.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Standard Care Home Subscription — £2,500/year per care home
ModelSubscriptionBilling cadenceAnnual
Notes

£2,500 per year per care home (excl. VAT). Includes: unlimited platform access, full onboarding and live support, outcomes and evidence reporting, unlimited training per site. No per-user fees, no hidden charges.

ayla-care.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1CST-Therapist Companion
Description

Digital dementia therapy tool designed to help care teams deliver Cognitive Stimulation Therapy in clinical and care home settings.

ayla-care.com
+1 more record
Core offering1 text field

Brain+ develops and sells digital therapeutics software that enables care teams to deliver Cognitive Stimulation Therapy (CST) for dementia patients. Its flagship product Ayla is a SaaS platform providing a structured 14-session CST programme with over 180 evidence-based activities, on-screen facilitator guidance, outcome tracking for CQC and family reporting, and a recognised staff qualification pathway, sold as a £2,500/year subscription per care home. The company also offers CST-Therapist Companion for Danish municipal dementia care and is developing CST-Home Care for home-based therapy delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Delays cognitive decline by 4–6 months — comparable to medication outcomes for dementia
+3 more records
Product overview1 text field

Brain+ offers a portfolio of digital dementia therapy products centered on Cognitive Stimulation Therapy (CST). The primary products include Ayla (a UK-focused CST delivery platform for care homes and memory clinics), CST-Therapist Companion (targeting Danish municipal healthcare), and CST-Home Care (a product in development for home-based therapy). Ayla serves as the flagship consumer-facing product with structured 14-session CST programs, over 200 activities, outcome tracking, and regulatory compliance features, while CST-Therapist Companion and CST-Home Care represent geographic and use-case expansions into institutional and home-based dementia care markets.

Product and service3 records
1Ayla
CategoryDigital therapeutics / dementia care software
Description

Ayla is the UK's first digital tool designed to help care teams deliver Cognitive Stimulation Therapy (CST) with ease. It provides a 14-session CST programme aligned to the official CST Manual, over 200 evidence-based activities, on-screen guidance with no prep required, one-day training for carers and activity staff, and outcome tracking for CQC and family reporting. It is sold to UK care homes, NHS memory clinics, and primary care providers as a £2,500/year per-care-home subscription.

2CST-Therapist Companion
CategoryDigital therapeutics / dementia care software
Description

CST-Therapist Companion is a digital dementia therapy product designed to enhance the commercialisation of Cognitive Stimulation Therapy across Danish municipalities, supporting implementation and scaling of therapist-led CST delivery in Danish municipal care services.

3CST-Home Care
CategoryDigital therapeutics / home dementia care software
Description

CST-Home Care is a digital Cognitive Stimulation Therapy product in development that aims to extend Brain+'s dementia therapy delivery into patients' homes, enabling family caregivers and patients living independently to access guided CST sessions outside clinical and care home settings.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Seven Danish Municipalities
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-23
Description

Seven Danish municipalities are collaborating with Brain+ on a project (supported by the Danish Business Promotion Board grant nomination) to scale the CST-Therapist Companion software into municipal dementia care. These municipal partners are directly involved in piloting and implementing the digital therapy across their care services.

in.marketscreener.com
2Danish Alzheimer's Association
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-23
Description

The Danish Alzheimer's Association (Alzheimerforeningen) is collaborating with Brain+ on the project to scale CST-Therapist Companion into Danish dementia care. As the leading patient advocacy organisation for dementia in Denmark, the Association provides clinical legitimacy, patient community access, and strategic guidance for the digital therapy rollout.

in.marketscreener.com
3DanAge
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-11-23
Description

DanAge (a Danish organisation focused on aging and older adults) is a project collaborator with Brain+ and the seven municipalities on scaling the digital dementia therapy. DanAge contributes expertise on the needs of aging populations and helps ensure the therapy meets the practical requirements of Danish elderly care services.

in.marketscreener.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NeuronUP is a digital platform that provides cognitive stimulation and neurorehabilitation activities for professionals working with older adults and patients with cognitive impairment. It directly competes with Brain+ in offering structured, evidence-based cognitive stimulation content to care homes and clinicians, with overlapping activities, personalisation, and outcome tracking features.

TypeDirect peer
Description

Active Cues develops the Tovertafel, an interactive projection-based games system for people with dementia and intellectual disabilities, widely deployed in UK and European care homes. It competes for the same care home activity budget as Brain+ Ayla, offering dementia engagement content, though delivered through projected games rather than a structured CST programme.

TypeDirect peer
Description

Memory Lane Games builds dementia-friendly quiz and reminiscence apps deployed in UK care homes and NHS settings. It is a direct peer to Brain+ Ayla in targeting activity coordinators and dementia leads with digital tools that deliver cognitive engagement and reminiscence content to care home residents.

TypeBroad incumbent
Description

Posit Science's BrainHQ is one of the most established clinically validated brain-training platforms, used in research and by older adults for cognitive exercises. It is a broad incumbent in the digital cognitive training category, overlapping with Brain+ in the underlying cognitive stimulation domain though lacking Brain+'s CST-specific clinical alignment and UK care home focus.

TypeEmerging player
Description

Constant Therapy is a digital cognitive, speech, and language therapy platform used by clinicians and patients recovering from stroke, TBI, and dementia. It is an emerging player in digital cognitive rehabilitation that overlaps with Brain+ in dementia cognitive therapy delivery but is broader in clinical indication and more clinician-led.

TypeDirect peer
Description

Active Minds is a UK-based company designing activities, games, and resources specifically for people with dementia, sold to care homes and dementia services. It competes directly with Brain+ Ayla for the UK care home activity budget, though its offering is predominantly physical products and puzzles rather than a CST software platform.

TypeEmerging player
Description

MindMate is a digital brain health app offering cognitive exercises, lifestyle content, and dementia-friendly activities for users and caregivers. It is an emerging player that intersects with Brain+ in the dementia cognitive engagement category, though primarily consumer-facing rather than focused on UK care home CST delivery.

8Music Health (Vera)
TypeEmerging player
Description

Music Health's Vera is a music therapy app for people with dementia, deployed in care homes and used by caregivers. It is an emerging player in the broader non-pharmacological dementia therapy category that overlaps with Brain+'s care home channel and dementia engagement mission, though focused on music rather than CST.

TypeOthers
Description

Alzheimer's Society is the UK's leading dementia charity and an advocacy, information, and service-delivery organisation for people with dementia and their families. It is adjacent rather than competitive, serving as a potential partner, content validator, and demand-signaling channel for Brain+ Ayla in the UK dementia ecosystem.

TypeEmerging player
Description

Cognivive develops digital therapeutics targeting cognitive function in neurological conditions, including dementia. It is an emerging player in the digital dementia therapeutics category with partial overlap to Brain+'s CST-aligned platform, though with a different therapeutic mechanism and earlier-stage commercial footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brain+

Digital Therapeutics / Dementia Care Softwarebrain-plus.com

Brain+ A/S is a Danish digital therapeutics company developing mobile and web applications that deliver evidence-based Cognitive Stimulation Therapy for dementia patients. It serves UK care homes, NHS memory clinics, Danish municipalities, and home-based dementia care through its Ayla, CST-Therapist Companion, and CST-Home Care products.

What Brain+ does

Brain+ A/S is a Danish digital therapeutics company founded in 2012 and headquartered in Copenhagen, operating with a headcount of 11–50 employees. The company develops mobile and web applications that deliver evidence-based Cognitive Stimulation Therapy (CST) for people with dementia, positioned as the only non-drug dementia therapy recommended by NICE and endorsed by Cochrane Reviews and SCIE. Its product portfolio centers on three offerings: Ayla, a UK-focused digital CST delivery platform for care homes and NHS memory clinics; CST-Therapist Companion, a Danish municipal channel product being scaled through a seven-municipality consortium with the Danish Alzheimer's Association and DanAge; and CST-Home Care, a product in development to extend therapy into patients' homes with family caregiver support.

The underlying platform combines a structured 14-session CST programme aligned to the official CST Manual, a library of over 180–200 clinically validated activities tagged by cognitive, physical, and emotional requirements, on-screen facilitator guidance that eliminates session preparation, and an outcomes-tracking framework that produces evidence aligned to the UK Single Assessment Framework and CQC reporting requirements. Brain+ monetizes Ayla via an annual SaaS subscription priced at £2,500 per care home per year, with no per-user fees and unlimited onboarding, training, and reporting included. Distribution is direct via the company website with a sales-led motion combining demo booking and quote-request CTAs, targeting care home CEOs, owners, managers, and activity coordinators, alongside NHS memory clinics and primary care providers.

The company's commercial strategy relies heavily on non-dilutive public funding: it secured three Danish public grants in 2023 totaling approximately DKK 7 million (including a DKK 3.5M Danish Business Authority grant for CST-Therapist Companion commercialization and an EUopSTART grant from the Danish Innovation Fund supporting an EIC Accelerator application for CST-Home Care). Geographic footprint is limited to the United Kingdom and Denmark, with no disclosed presence in other markets. The company is privately held and appears to be in an early commercial stage, using public grants in lieu of equity dilution to fund product and geographic expansion.

Brain+ firmographics

Firmographics
Name
Brain+
Legal name
Brain+ A/S
Website
https://brain-plus.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Brain+ A/S is a Danish digital therapeutics company developing mobile and web applications that deliver evidence-based Cognitive Stimulation Therapy for dementia patients. It serves UK care homes, NHS memory clinics, Danish municipalities, and home-based dementia care through its Ayla, CST-Therapist Companion, and CST-Home Care products.
Ownership category
akta.pro rank

Brain+ industry classification

Industry
Product category
Digital Therapeutics / Dementia Care Software
NAICS
Services for the Elderly and Persons with Disabilities (62412), Home Health Care Services (6216)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Home Health Care Services (8082), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
SECONDARYHSABAEAJ
Dementia Care Coordination & Care Planning
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)

Keywords

  • Digital dementia therapy
  • Cognitive stimulation therapy
  • Dementia care software
  • Digital therapeutics platform
  • Care home technology

Where Brain+ is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Brain+ business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Annual Care Home Subscription: SaaS subscription model charging a flat annual fee per care home. Includes unlimited platform access, full onboarding and live support, outcomes reporting, and unlimited staff training per site. No per-user fees or hidden charges. Single pricing tier at £2,500/year per care home.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualStandard Care Home Subscription — £2,500/year per care home

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Brain+ product offering

Product offering

Core offering

Brain+ develops and sells digital therapeutics software that enables care teams to deliver Cognitive Stimulation Therapy (CST) for dementia patients. Its flagship product Ayla is a SaaS platform providing a structured 14-session CST programme with over 180 evidence-based activities, on-screen facilitator guidance, outcome tracking for CQC and family reporting, and a recognised staff qualification pathway, sold as a £2,500/year subscription per care home. The company also offers CST-Therapist Companion for Danish municipal dementia care and is developing CST-Home Care for home-based therapy delivery.

Product overview

Brain+ offers a portfolio of digital dementia therapy products centered on Cognitive Stimulation Therapy (CST). The primary products include Ayla (a UK-focused CST delivery platform for care homes and memory clinics), CST-Therapist Companion (targeting Danish municipal healthcare), and CST-Home Care (a product in development for home-based therapy). Ayla serves as the flagship consumer-facing product with structured 14-session CST programs, over 200 activities, outcome tracking, and regulatory compliance features, while CST-Therapist Companion and CST-Home Care represent geographic and use-case expansions into institutional and home-based dementia care markets.

Differentiator

Problem solved

Functional benefit

Brands

  • CST-Therapist Companion: Digital dementia therapy tool designed to help care teams deliver Cognitive Stimulation Therapy in clinical and care home settings.
  • CST-Home Care

Products and services

  • Ayla Ayla is the UK's first digital tool designed to help care teams deliver Cognitive Stimulation Therapy (CST) with ease. It provides a 14-session CST programme aligned to the official CST Manual, over 200 evidence-based activities, on-screen guidance with no prep required, one-day training for carers and activity staff, and outcome tracking for CQC and family reporting. It is sold to UK care homes, NHS memory clinics, and primary care providers as a £2,500/year per-care-home subscription.
  • CST-Therapist Companion CST-Therapist Companion is a digital dementia therapy product designed to enhance the commercialisation of Cognitive Stimulation Therapy across Danish municipalities, supporting implementation and scaling of therapist-led CST delivery in Danish municipal care services.
  • CST-Home Care CST-Home Care is a digital Cognitive Stimulation Therapy product in development that aims to extend Brain+'s dementia therapy delivery into patients' homes, enabling family caregivers and patients living independently to access guided CST sessions outside clinical and care home settings.

Quantifiable outcome

  • Delays cognitive decline by 4–6 months — comparable to medication outcomes for dementia
  • +3 more outcomes

Companies that use Brain+

Customer profile

Segments4 records

Ideal customer profiles3 records

Brain+ technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Brain+ partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Seven Danish MunicipalitiescoreStrategic or Co-development Partner · 23 November 2023Seven Danish municipalities are collaborating with Brain+ on a project (supported by the Danish Business Promotion Board grant nomination) to scale the CST-Therapist Companion software into municipal dementia care. These municipal partners are directly involved in piloting and implementing the digital therapy across their care services.
  • Danish Alzheimer's AssociationcoreStrategic or Co-development Partner · 23 November 2023The Danish Alzheimer's Association (Alzheimerforeningen) is collaborating with Brain+ on the project to scale CST-Therapist Companion into Danish dementia care. As the leading patient advocacy organisation for dementia in Denmark, the Association provides clinical legitimacy, patient community access, and strategic guidance for the digital therapy rollout.
  • DanAgesupportingStrategic or Co-development Partner · 23 November 2023DanAge (a Danish organisation focused on aging and older adults) is a project collaborator with Brain+ and the seven municipalities on scaling the digital dementia therapy. DanAge contributes expertise on the needs of aging populations and helps ensure the therapy meets the practical requirements of Danish elderly care services.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Brain+ competitors and assessment

Company assessment

Direct peers

  • NeuronUP: NeuronUP is a digital platform that provides cognitive stimulation and neurorehabilitation activities for professionals working with older adults and patients with cognitive impairment. It directly competes with Brain+ in offering structured, evidence-based cognitive stimulation content to care homes and clinicians, with overlapping activities, personalisation, and outcome tracking features.
  • Active Cues (Tovertafel): Active Cues develops the Tovertafel, an interactive projection-based games system for people with dementia and intellectual disabilities, widely deployed in UK and European care homes. It competes for the same care home activity budget as Brain+ Ayla, offering dementia engagement content, though delivered through projected games rather than a structured CST programme.
  • Memory Lane Games: Memory Lane Games builds dementia-friendly quiz and reminiscence apps deployed in UK care homes and NHS settings. It is a direct peer to Brain+ Ayla in targeting activity coordinators and dementia leads with digital tools that deliver cognitive engagement and reminiscence content to care home residents.
  • Active Minds: Active Minds is a UK-based company designing activities, games, and resources specifically for people with dementia, sold to care homes and dementia services. It competes directly with Brain+ Ayla for the UK care home activity budget, though its offering is predominantly physical products and puzzles rather than a CST software platform.

Broad incumbents

  • Posit Science (BrainHQ): Posit Science's BrainHQ is one of the most established clinically validated brain-training platforms, used in research and by older adults for cognitive exercises. It is a broad incumbent in the digital cognitive training category, overlapping with Brain+ in the underlying cognitive stimulation domain though lacking Brain+'s CST-specific clinical alignment and UK care home focus.

Emerging players

  • Constant Therapy: Constant Therapy is a digital cognitive, speech, and language therapy platform used by clinicians and patients recovering from stroke, TBI, and dementia. It is an emerging player in digital cognitive rehabilitation that overlaps with Brain+ in dementia cognitive therapy delivery but is broader in clinical indication and more clinician-led.
  • MindMate: MindMate is a digital brain health app offering cognitive exercises, lifestyle content, and dementia-friendly activities for users and caregivers. It is an emerging player that intersects with Brain+ in the dementia cognitive engagement category, though primarily consumer-facing rather than focused on UK care home CST delivery.
  • Music Health (Vera): Music Health's Vera is a music therapy app for people with dementia, deployed in care homes and used by caregivers. It is an emerging player in the broader non-pharmacological dementia therapy category that overlaps with Brain+'s care home channel and dementia engagement mission, though focused on music rather than CST.
  • Cognivive: Cognivive develops digital therapeutics targeting cognitive function in neurological conditions, including dementia. It is an emerging player in the digital dementia therapeutics category with partial overlap to Brain+'s CST-aligned platform, though with a different therapeutic mechanism and earlier-stage commercial footprint.

Others

  • Alzheimer's Society: Alzheimer's Society is the UK's leading dementia charity and an advocacy, information, and service-delivery organisation for people with dementia and their families. It is adjacent rather than competitive, serving as a potential partner, content validator, and demand-signaling channel for Brain+ Ayla in the UK dementia ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Brain+ social profiles

Digital presence

Brain+ compliance and trust

Trust signal

Compliance1 record

Brain+ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brain+ leadership team

Management profile

Number of profiles

Profiles3 records

Brain+ funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brain+ M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brain+

What does Brain+ do?

Brain+ develops and sells digital therapeutics software that enables care teams to deliver Cognitive Stimulation Therapy (CST) for dementia patients. Its flagship product Ayla is a SaaS platform providing a structured 14-session CST programme with over 180 evidence-based activities, on-screen facilitator guidance, outcome tracking for CQC and family reporting, and a recognised staff qualification pathway, sold as a £2,500/year subscription per care home. The company also offers CST-Therapist Companion for Danish municipal dementia care and is developing CST-Home Care for home-based therapy delivery.

Is Brain+ a public or private company?

Brain+ is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Brain+ founded?

Brain+ was founded in 2024. It employs 11 to 50 people.

Where is Brain+ based?

Brain+ is headquartered in London, United Kingdom, in the Europe region.

How does Brain+ make money?

One revenue line is on record: annual Care Home Subscription.

Who are Brain+'s main competitors?

Direct peers on record are NeuronUP, Active Cues (Tovertafel), Memory Lane Games and Active Minds. Posit Science (BrainHQ) is listed as a broad incumbent. Emerging players are Constant Therapy, MindMate, Music Health (Vera) and Cognivive. Alzheimer's Society is listed as an others.

Does Brain+ have an API?

No public API is recorded for Brain+.

What industry is Brain+ in?

Brain+'s product category is Digital Therapeutics / Dementia Care Software. Its primary akta.pro industry code is HSABAEAH, Cognitive Stimulation & Reminiscence Therapy (Non-Clinical), with a secondary code of HSABAEAJ, Dementia Care Coordination & Care Planning. Its NAICS code is 62412 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewBrain+ selected for the NHS Dementia Innovators Programme in the UKBrain+ A/S was selected for the UK NHS Dementia Innovators Programme, a pilot by NHS CEP and Alzheimer's Society. The selection validates its Ayla dementia care platform and is expected to advance commercial uptake in NHS institutions over the next 12-18 months.TradingViewBrain+ to close first UK Care Home partnership contract with Southcare Homes GroupBrain+ A/S signed a 12-month partnership with Southcare Homes Group to deploy its Ayla cognitive stimulation therapy assistant in two of Southcare's five care sites. The contract includes accredited CST training for caregivers and marks the first UK care home deployment of Ayla. The exact contract value was not disclosed.TradingViewInvitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights IssueBrain+ A/S will host an investor webinar on 21 March 2025 to present a new board observer, sales pipeline progress, and the ongoing Unit Rights Issue. The sales pipeline now represents over €500,000 in revenues, and the rights issue runs from 17 to 28 March 2025.Brain-PlusBrain+ Helping people affected by dementia live better livesBrain+ is promoting its digital Cognitive Stimulation Therapy (CST) platform, Ayla, which utilizes an AI assistant to deliver clinically validated sessions for dementia patients. The company highlights that this technology can delay cognitive decline by 4-6 months and reduce preparation time for healthcare providers by 50%. Brain+ is actively seeking input from patients, carers, and investors to support the development of its Home Companion product.FrontiersPractical guidelines for developing digital health solutions to increase equity in dementia care in the UKA scoping review of 34 publications identified equity frameworks and design principles for digital health solutions, leading to practical guidelines for developers. The guidelines aim to increase equitable access to dementia care in the UK, using the Brain+ CST Assistant app as a use case. Future research could test usability and explore institutional barriers to adoption.Tech.euWhy Denmark is a hotbed for healthtech startups and innovationDanish healthtech startups raised $835 million in 2023, an 11% increase from 2021, while most of Europe saw a 37% drop in VC investment. The country's digital-first healthcare system, with 99% of citizens having electronic health records, supports innovation. Five companies—Brain+, Konfront, Human Bytes, Precure, and Femilog—are highlighted as notable examples.NasdaqBrain+ completes the implementation of an ISO 13485 Quality Management System for Medical DevicesBrain+ A/S, a Copenhagen-based digital therapeutics company focused on Alzheimer's disease, has completed implementation of an ISO 13485-compliant Quality Management System, marking a key compliance milestone for software-based medical device development. This certification is required by large healthcare customers, pharmaceutical partners, and government reimbursement systems including Germany's DiGA and DiPA schemes. The company states the QMS positions it to pursue pharma partnerships and scale product reimbursement, with an investor webinar scheduled for December 22, 2022.news.cision.comCommon Nordic digital health evaluation framework launchedNordDEC, a Nordic digital health evaluation framework, was launched in June 2022 to unify standards across Sweden, Denmark, Norway, Finland, and Iceland. It aims to differentiate evidence-based digital therapeutics from unregulated health apps, with Brain+ targeting dementia care. The framework may support future reimbursement pathways.news.cision.comBrain+ and Biogen preparing for commercialization in Germany, the #1 EU market for digital therapeuticsBrain+ was selected for Biogen and EIT Health's Neurotech-prize program to support its first dementia product launch in Germany in 2023. The program provides mentorship and a €100,000 prize for the top solution among nine candidates. Success in Germany is seen as a base for global expansion.